BridgeBio Pharma Inc vs Zillow Group Inc Class A — how do they compare? BridgeBio Pharma Inc trades at $84.08 (market cap $16.36B), while Zillow Group Inc Class A trades at $34.4 (market cap $7.68B). The key difference: BridgeBio Pharma Inc is far larger — about 2.1× Zillow Group Inc Class A's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| BBIO | ZG | |
|---|---|---|
Market Cap | $16.36B | $7.68B |
Sector | Health | Media |
52-Week High | $90.17 | $86.76 |
52-Week Low | $47.29 | $29.14 |
Enterprise Value | $18.14B | $7.56B |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.
Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.
Zillow Group (ZG) trades at $33.46, down 1.81% with a bearish technical signal. The company shows improving fundamentals with Q2 2026 earnings beats and 18% revenue growth, though net margins remain thin at 1.96%. Recent news highlights strong performance in the preferred agent model but is overshadowed by multiple securities class action lawsuits with August 2026 deadlines. Valuation metrics appear elevated with a P/E of 149, while analyst consensus targets $47.56 with mixed ratings.
The outlook is cautiously optimistic given ZG's business model transition and revenue growth, but significant legal overhangs and high valuation create near-term risks. Long-term potential exists if monetization improvements continue, though investors should weigh legal uncertainties against fundamental progress.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →